Phase II Trial Will Test Pembrolizumab in Oligometastatic Lung Cancer Patients
Lung cancer News, News
A phase II clinical trial for patients with oligometastatic lung cancer will test the new immunotherapy drug pembrolizumab. This drug acts specifically on T cells and blocks the programmed death receptor (PD-1) ... Read more